Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and above~* First diagnosis of C. difficile infection~* Treatment for C. difficile infection less than 24 hours~* Female subjects must be nonpregnant, nonlactating, and either postmenopausal for at least 1 year, surgically sterile (i.e., documented tubal ligation or hysterectomy) for at least 90 days, abstinent, or agree to use 1 of the following forms of contraception from the time of signing the Informed Consent form (ICF) until 30 days after leaving the study site: a nonhormonal intrauterine device (IUD) with spermicide, female condom with spermicide, contraceptive sponge with spermicide, diaphragm with spermicide, cervical cap with spermicide, a male sexual partner who agrees to use a male condom with spermicide, or a sterile sexual partner.~Exclusion Criteria:~* History of hypersensitivity to fidaxomicin or vancomycin~* Pregnant or breast-feeding~* Active treatment with other therapies with activity against C. difficile~* Receiving any peristaltic agents~* Medical history including ulcerative colitis or Chron's disease~* Ordered to be nothing by mouth or cannot swallow the study medication~* Participation in another clinical research study utilizing pharmacological treatment within 1 month or five half-lives of the medication whichever is longer~* Any other reason felt by the investigator to potentially affect the outcomes of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fidaxomicin (Type: ACTIVE_COMPARATOR): Fidaxomicin 200mg by mouth every 12 hours for 10 days
- Vancomycin (Type: ACTIVE_COMPARATOR): Vancomycin 125mg by mouth every 6 hours for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).